Home  >  Products  >  NAPRT1 (nicotinate phosphoribosyltransferase domain containing 1 ) Blocking Peptide (the C terminal of NAPRT1)(100ug)
NAPRT1 (nicotinate phosphoribosyltransferase domain containing 1 ) Blocking Peptide (the C terminal of NAPRT1)(100ug)

NAPRT1 (nicotinate phosphoribosyltransferase domain containing 1 ) Blocking Peptide (the C terminal of NAPRT1)(100ug)

Supplier: Aviva Systems Biology Incorporated
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
This is a synthetic peptide designed for use in combination with anti-NAPRT1 Antibody (ARP62878_P050), made by Aviva Systems Biology. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.
Reactivities: Human
Presku: AAP62878
Size: 100ug
Weight: 51kDa
Gene: The peptide is characterized by mass spectroscopy
Format: Lyophilized powder
Target: Nicotinic acid (NA; niacin) is converted by nicotinic acid phosphoribosyltransferase (NAPRT; EC 2.4.2.11) to NA mononucleotide (NaMN), which is then converted to NA adenine dinucleotide (NaAD), and finally to nicotinamide adenine dinucleotide (NAD), which serves as a coenzyme in cellular redox reactions and is an essential component of a variety of processes in cellular metabolism including response to stress.
Alternative names: PP3856
See Full Product Listings >